In recent years, Bruton’s tyrosine kinase (BTK), a member of the TEC (tyrosine kinase expressed in hepatocellular carcinoma) family of non-receptor tyrosine kinases (NRTKs), has emerged as a key target in the suppressive phenotypes of MDSCs and TAMs. The gene discussed is BTK; the disease is hepatocellular carcinoma.